Enanta Pharmaceuticals (ENTA) said Thursday that a phase 2a study evaluating EDP-323 in adults with respiratory syncytial virus, or RSV, met its primary and secondary endpoints.
Reductions of 85% to 87% in viral load area under the curve, 97% to 98% in infectious viral load AUC, and 66% to 78% in overall symptoms were observed across the trial, Enanta said. All endpoints were met with "highly statistically significant" results, the company added.
The company also said EDP-323 was observed to be generally safe and well-tolerated, with no serious or severe adverse events, over a five-day dosing period and through 28 days of follow-up.
Shares of the company were up 3.2% in recent premarket activity.
Price: 11.01, Change: +0.34, Percent Change: +3.19
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。